BiologicalDrug
Oblimersen clinical trials
Also written G3139, Genasense and augmerosen.
- studies test it
- 38
- open now
- 0
- in phase 3
- 8
- first study started
- 2000
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2003 (10)
| Year | Studies |
|---|---|
| 2000 | 3 |
| 2001 | 3 |
| 2002 | 7 |
| 2003 | 10 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 15
- Phase 2
- 20
- Phase 3
- 8
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 26
National Cancer Institute (NCI) (18) · Genta Incorporated (12) · University of Maryland, Baltimore (1) · University Health Network, Toronto (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · The University of Texas Health Science Center at San Antonio (1) · British Columbia Cancer Agency (1) · University of Nebraska (1)
Often tested with
Tested in the same studies.
Rituximab (4) · Doxorubicin (3) · Dacarbazine (3) · Paclitaxel (3) · Docetaxel (3) · Dexamethasone (2) · Cyclophosphamide (2) · Imatinib (2)
Studies
Open first, then newest update. How each study uses oblimersen is read from its arms, and is right about nine times in ten.
Testing it · 38
- Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 3National Cancer Institute (NCI)NCT00085124Written as oblimersen sodium
- Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaTerminatedEarly Phase 1University of NebraskaNCT00736450Written as oblimersen sodium
- A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT00064259Written as oblimersen sodium
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 2University of Maryland, BaltimoreNCT00049374Written as oblimersen sodium
- Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT00063934Written as oblimersen sodium
- Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)CompletedPhase 2University Health Network, TorontoNCT00047229Written as oblimersen sodium
- Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal MelanomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT01200342Written as Genasense
- Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedPhase 1National Cancer Institute (NCI)NCT00039117Written as oblimersen sodium
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT00054639Written as oblimersen sodium
- Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedPhase 2Genta IncorporatedNCT00017589Written as oblimersen sodium
- Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedPhase 3Genta IncorporatedNCT00024440Written as oblimersen sodium
- Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 3Genta IncorporatedNCT00017602Written as oblimersen sodium
- Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant MelanomaCompletedPhase 3Genta IncorporatedNCT00016263Written as oblimersen sodium
- Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301Status unknownNot applicableJonsson Comprehensive Cancer CenterNCT00070343Written as oblimersen sodium
- Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung CancerStatus unknownPhase 2/3Genta IncorporatedNCT00030641Written as oblimersen sodium
- Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell CancerCompletedPhase 2National Cancer Institute (NCI)NCT00059813Written as oblimersen sodium
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedPhase 2National Cancer Institute (NCI)NCT00091078Written as oblimersen sodium
- Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedPhase 2National Cancer Institute (NCI)NCT00079131Written as oblimersen sodium
- Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's MacroglobulinemiaCompletedPhase 1/2National Cancer Institute (NCI)NCT00062244Written as oblimersen sodium
- Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00049192Written as oblimersen sodium
See all 38 studies that test oblimersen →
Given in every arm · 4 — oblimersen is usual care beside what is tested
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)RecruitingPhase 1Bio-Path Holdings, Inc.NCT05190471Written as BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung CancerCompletedPhase 1/2University of ChicagoNCT00005032Written as oblimersen sodium
- Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedPhase 1National Cancer Institute (NCI)NCT00004862Written as oblimersen sodium
- A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without DacarbazineCompletedPhase 1Genta IncorporatedNCT00542893Written as Genasense® (G3139, oblimersen sodium)
Codes
What other systems call oblimersen · ClinicalTrials.gg INT004234
- MeSH (NLM) C408162oblimersenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 85J5ZP6YSLOBLIMERSENConfirmed FDA, NLM
- NCI Thesaurus C1870OblimersenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C408162 | oblimersen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 85J5ZP6YSL | OBLIMERSEN | Confirmed FDA, NLM |
| NCI Thesaurus | C1870 | Oblimersen | One source FDA |
Also registered as oblimersen sodium (UNII SH55B0RQ9K).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.